Kornimate/medical-research-clean huggingface dataset:
gnao1 natural history study

Conditions: GNAO1

Summary: the purpose of the gnao1 natural history study is to establish the clinical phenotype of gnao1 associated neurologic disease, its association with genotype, and areas of clinical importance within the disease.

gnao1 associated neurologic disease is a rare autosomal dominant neurodevelopmental disorder characterized genetically by heterozygous de novo mutations in gnao1 gene which encodes gαo, the α subunit of go, a g protein signal transducer. phenotypically, it is characterized by developmental delay, epilepsy and/or movement disorder. medical therapy is symptomatic and often ineffective for many patients. while there are basic and translational studies underway to develop more mechanistic treatments aimed at developing disease modifying treatments, our general knowledge of the natural history of gnao1 associated neurologicis is extremely limited, making it difficult to select the best measures for identifying changes over time. without this information,it will be difficult to detect any potential therapeutic efficacy in future trials of novel therapies. to address this critical void in our understanding, we propose to retrospectively and prospectively examine symptom progression(short-and long-term)and developmental outcomes in patients with gnao1 associated neurologic disease. retrospective data will be collected on a cohort of 50 patients. standardized historical clinical information will be received from the physicians and care-givers of these patients, in collaboration with the bow foundation registry. these data will provide an overview of the onset and severity of symptoms over development. in addition, prospective data will be acquired during in-person clinical evaluations of a cohort of 15-20 patients who are not receiving any experimental interventions. in combination, these two approaches will provide critical information about the natural history of gnao1 associated neurologic disease in children, identify metrics that track change most reliably over time, and collect pilot data for larger future studies.

Eligibility criteria:
inclusion criteria: * enrollment in the bow foundation gnao1 registry. * evidence of a known pathogenic mutation in gnao1 or a variant of unknown significance and clinical symptoms likely to be consistent with gnao1 as determined by study physicians. exclusion criteria: * inability to obtain informed consent from parents or adult subjects. * inability to obtain medical records.

Keywords: natural history study pediatric neurology movement disorder epilepsy gnao1
tramadol iv. : influence of dose and dose intervals on therapeutic accuracy and side effects when used for postoperative pain relief in ambulatory surgery

Conditions: Ambulatory Surgery

Summary: the aim of this study is to compare the administration of 1 unit dose of 100 mg tramadol intravenously versus multiple smaller dosages of tramadol during the first 6 hours post-operatively and to investigate the time course and accuracy of pain relief versus the onset and duration of side-effects.


Eligibility criteria:
inclusion criteria: * asa i and ii female or male patients * aged 18-70 years * scheduled for ambulatory surgery requiring postoperative pain medication. exclusion criteria: * weight less than 70% or more than 130% of ideal body weight * neurological disorder * recent use of psycho-active medication, including alcohol * patients suffering from chronic pain receiving pre-operative pain medication including nsaid's * use of chronic anti-emetic medication, use of chronic corticoid therapy
comparison of high-dose rosuvastatin versus low-dose rosuvastatin plus ezetimibe on carotid plaque inflammation in patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome; Carotid Atherosclerotic Plaque With Inflammation

Summary: combination therapy of ezetimibe with a low-dose statin is occasionally used to avoid statin-related side effects in clinical practice among patients with atherosclerotic cardiovascular disease. this approach is equivalent to high-dose statin therapy to decrease ldl cholesterol level by \>50%, allowing such patients to achieve ldl cholesterol target. however, it remains uncertain whether combination therapy with ezetimibe and low-dose statin verse high-dose statin monotherapy similarily suppress atherosclerotic plaque inflammation. this study is to compare high-dose rosuvastatin versus low-dose rosuvastatin plus ezetimibe on carotid plaque inflammation in patients with acute coronary syndrome using 18f-fluorodeoxyglucose (18fdg) positron emission tomography (pet) imaging.


Eligibility criteria:
inclusion criteria: 1. aged ≥ 19 years 2. acute coronary syndrome, carotid artery disease (diameter stenosis 20-50%), and at least one 18fdg uptake lesion in the carotid artery (target to background ratio (tbr) ≥ 1.6) by 18fdg pet/ct imaging 3. written consent exclusion criteria: 1. previous history of carotid endarterectomy or stenting 2. schedule for cardiac or major surgery within the next 6 months 3. statin or ezetimibe therapy in the past 4 weeks 4. chronic disease needed to be treated with oral, intravenous, or intraarticular steroid 5. end-stage renal disease 6. chronic liver disease 7. history of cancers within the past 3 years 8. pregnant, breast-feeding or child-bearing potential 9. expected life expectancy within 2 years

Keywords: rosuvastatin ezetimibe/rosuvastatin carotid plaque inflammation fluorodeoxyglucose f18 positron emission tomography
compare the aesthetic effect of different thyroidectomies

Conditions: Differentiated Thyroid Carcinoma (DTC)

Summary: one hundred twenty female patients who underwent thyroidectomy were evenly distributed into three groups: conventional access (ca), aesthetic principles access (apa) and minimally invasive access (mia). the patient and observer scar assessment scale (posas) was used as the assessment tool for the linear scar. after one year follow-up, the cosmetic outcomes were assessed.

a prospective study in patients with dtc at the department of head and neck surgery at perking university cancer hospital (also called beijing cancer hospital). a total of 120 female patients who underwent surgical treatment for dtc were enrolled in the study from june 2012 to june 2014. all patients were diagnosed with dtc through preoperative fine needle aspiration biopsy pathology. these patients were individually randomly assigned (1:1:1 ratio) into the conventional access group (ca), the aesthetic principles access group (apa) or the minimally invasive access group (mia). lobectomy plus ipsilateral central lymph node dissection (clnd) was adopted in each patient. dtc staging was t1n0m0 or t1n1m0. the investigators retrieved the patients' information, including age, incision length, incision closure procedure, incidence of complications, and cosmetic assessment from patients' medical records. patients with other medical diseases, such as diabetes or obesity, a smoking history, a keloid tendency, a history of radiotherapy to the head and neck, or with incomplete information, were excluded. rln function was evaluated by electronic fiber laryngoscopy 6 months postoperatively. the follow-up time was 12.3 months. the research was reviewed and approved by the ethics committee of peking university cancer hospital, and informed consent was obtained from all patients to publish the information/image(s) in an online open-access publication. the study was open-label with no blinding of patients, clinicians, or research staff.

Eligibility criteria:
inclusion criteria: * patients diagnosed with dtc through preoperative fine needle aspiration biopsy pathology. * dtc staging was t1n0m0 or t1n1m0. * female * age over 18 years * subjects who fully understand the study process, participate voluntarily exclusion criteria: * patients with other medical diseases, such as diabetes or obesity, a smoking history, a keloid tendency, a history of radiotherapy to the head and neck, or with incomplete information.

Keywords: thyroid surgery thyroidectomy minimally invasive access aesthetic principle posas
retrospective clinical evaluation of nano-hybrid-composite denture teeth

Conditions: Edentulous Mouth; Dental Prosthesis Failure

Summary: this retrospective study investigates the longevity of dentures with sr phonares ii teeth after a wearing period of more than 10 years. the primary objective is to assess the survival rate of dentures with sr phonares ii teeth after more than 10 years. the secondary objectives asses the quality of the dentures concerning aesthetic, functional and biological properties.


Eligibility criteria:
inclusion criteria: * informed consent signed and understood by the subject * partial or full denture with sr phonares ii teeth * dentures delivered in the internal clinic between august 2010 and august 2012 * to be able to visit the internal clinic (exception: patients with limited mobility are also included if another person can carry the dentures to the internal clinic of ivoclar vivadent ag for the examination.) exclusion criteria: * patient does not wear the dentures regularly * health status (physical and mental) does not allow participation.
botulinum toxin a to treat arm tremor

Conditions: Essential Tremor of the Upper Limbs

Summary: the objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of nt 201, compared with placebo, in moderate to marked essential tremor of the upper limb.


Eligibility criteria:
main inclusion criteria: * diagnosis of 'definite essential tremor' in accordance with modified trig criteria, as follows: * bilateral postural tremor with or without kinetic tremor, involving hands and forearms, that is visible and persistent. * it is to be noted that: * tremor of other body parts may be present in addition to upper limb tremor. * bilateral tremor may be asymmetric. * tremor is reported by patient to be persistent, although the amplitude may fluctuate. * first onset of essential tremor at least 6 months before screening with stability of the tremor symptoms over 4 weeks and in the opinion of the investigator definite diagnosis of essential tremor. * moderate-to-marked upper-limb postural and/or kinetic tremor at wrist level, corresponding to fahn-tolosa-marin upper-limb tremor rating of at least 2 categories (scale part c, items 16-23) in the limb to be treated between of 2 or higher. * visible tremor at wrist level in at least one of the four positions/tasks used in kinematic assessments * tremor deemed by the investigator to require a treatment with 30 - 200 u nt 201 for a treatment of up to three joints of the selected upper limb (wrist treatment mandatory). * stable concomitant anti-tremor medication and no clinically relevant findings in routine laboratory examinations. main exclusion criteria: * any neurological signs abnormal for the subject's age, other than the tremor itself and froment's maneuver. * exposure to the following tremorogenic drugs: lithium, valproic acid, amiodarone, typical and atypical neuroleptics. exposure to other than the listed tremorogenic or potentially tremorogenic drugs is allowed only if, in the opinion of the investigator, this will not interfere with the study drug evaluation. in these cases, a stable medication should be reached 4 weeks before screening and intended for the time during the study drug evaluation. * trauma to the central nervous system or the nerves of the target limb within the three months preceding the onset of tremor. * evidence of psychogenic origins of tremor. * life habits (e.g. smoking, alcohol or substance abuse) prejudicial to study participation. * prior surgery to treat tremor * recent (16 weeks) treatment with any botulinum toxin product for any reason. * relevant recent or planned surgery or other specified relevant treatments and/or concomitant disorders.
low-dose naltrexone combined with bupropion to stop smoking with less weight gain

Conditions: Smoking; Nicotine Dependence

Summary: this study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.

this is an open label smoking cessation clinical trial of 25 mg naltrexone with 300 mg bupropion sustained-release (sr) in six male and fourteen female participants. this pilot study is being conducted to determine: * effect size estimates for smoking cessation and post-cessation weight gain, which will be used to compute the sample size needed for a large-scale clinical trial; and * compliance with a combination of 25 mg naltrexone and 300 mg bupropion sr. in addition to examining the sample in this study, the investigators plan to compare this sample to a sample of matched controls.

Eligibility criteria:
inclusion criteria: * ages 18 and older * willingness and ability to give written consent * smoking at least 10 cigarettes per day for at least 1 year * baseline expired carbon-monoxide level of at least 10 ppm * weigh at least 100 lbs. * english-speaking * one person per household * at least 1 prior quit attempt * concern about gaining weight. this will be assessed using a questionnaire that will provide a rating system to determine qualified participants. exclusion criteria: * pregnant or nursing women or women attempting to conceive * serious current neurologic, psychiatric or medical illness, including unstable cardiac, hepatic, or renal disease and diabetes and hypertension * current alcohol dependence * current use of opiates, and/or a urine toxicology screen positive for opiates * chronic pain conditions necessitating opioid treatment (naltrexone, an opioid antagonist will make these medications ineffective) * evidence of significant hepatocellular injury as evidenced by ast or alt \>3 x normal or elevated bilirubin * history of cirrhosis * body mass index (bmi) greater than 35 * history of anorexia nervosa or bulimia * current major depression * currently taking toprol-xl (or metoprolol succinate) * history of seizure disorder or serious brain injury * current use of smokeless tobacco, pipes, cigars, nicotine gum, nicotine patch, nicotine inhaler, nicotine lozenge, nicotine nasal spray, or bupropion * previous hypersensitivity to bupropion * patients requiring concomitant therapy with any psychotropic drug * participation in the framing messages for smoking cessation with bupropion study (hic#: 10880)

Keywords: tobacco smoking weight weight perception naltrexone bupropion
three different types of thermometers in measuring temperature in young patients with fever and without fever

Conditions: Fever, Sweats, and Hot Flashes

Summary: rationale: comparing results of three different thermometers used to measure body temperature may help doctors find the most accurate thermometer to detect fever and plan the best treatment. purpose: this clinical trial is studying three different types of thermometers to measure temperature in young patients with fever and without fever.

objectives: primary * determine agreement between three different types of temperature-measuring instruments: the temporal artery scanner, the digital oral thermometer, and the infrared tympanic thermometer calibrated to an oral setting, in pediatric patients who are febrile and afebrile. secondary * determine similarities or differences in the percent of fevers detected with oral, ear, and temporal artery monitoring in these pediatric patients. * determine differences in agreement of the various temperature devices in non-neutropenic pediatric patients versus neutropenic pediatric patients. outline: this is a prospective study. during an afebrile episode, the patient's temperature is measured twice using the following 3 devices: a temporal artery scanner, a digital oral thermometer, and an infrared tympanic thermometer calibrated to an oral setting (total of 6 temperature measurements per afebrile episode). during a febrile episode, the patient's temperature is measured twice using all 3 devices as above, and then at 2 and 4 hours after administration of an antipyretic medication (total of 18 temperatures per febrile episode). patients' temperatures are recorded for a maximum of 3 afebrile or febrile episodes. projected accrual: a total of 32 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * febrile or afebrile * patient at the mark o. harfield clinical research center * previously enrolled in an irb-approved clinical center protocol patient characteristics: * able to hold an oral thermometer in mouth * no acute life-threatening infection * no ear, nose, or throat (aural) abnormalities * no severe mucositis prior concurrent therapy: * see disease characteristics * no concurrent enrollment on a behavioral research study

Keywords: fever, sweats, and hot flashes
screening for chronic kidney disease (ckd) among older people across europe (scope)

Conditions: Chronic Kidney Diseases

Summary: the scope study is an observational, multicenter, prospective cohort study aimed at evaluating a 2-year screening programme for ckd in a population of older patients, aged 75 years or more, in seven european countries, in an attempt to investigate whether and to which extent currently available screening methods may identify older people at risk of worsening kidney function.


Eligibility criteria:
inclusion criteria: * age≥75 years * subjects attending the outpatient services at participating institutions exclusion criteria: * esrd or dialysis * history of solid organ or bone marrow transplantation * active malignancy within 24 months prior to screening or metastatic cancer * life expectancy less than 6 months * severe cognitive impairment (mmse\<10), * any medical or other reason that the subject is unsuitable for the study * subjects unwilling to provide consent

Keywords: chronic kidney diseases older geriatric assessment biomarkers
reposition of second line treatment in chronic immune thrombocytopenia

Conditions: Immune Thrombocytopenia

Summary: hydroxychloroquine has been reported to have a clinically significant effect on the platelet count in systemic lupus thrombocytopenia. its action may be due to its immune modulator effect. immune thrombocytopenia (itp) is known as an immune-mediated acquired disease characterized by transient or persistent decrease of the platelet count. however, refractory itp is lacking of effective treatments and the efficacy of decitabine in itp remains poorly understood. data from this study may provide some idea of hydroxychloroquine in the treatment of itp in comparison to other lines of treatment as detected by the standardized definitions.

this study will include patients with chronic itp attending the out patients clinic of clinical hematology unit of internal medicine department of assiut university hospital to evaluate the safety and efficacy of hydroxychloroquine in comparison to other lines of treatment as detected by the standardized definitions . detect the predictors for chronic itp especially anti-nuclear antibodies (ana) role and the effect of the proposed drugs on the level of anti-platelet antibodies. evaluation of the health-related quality of life after treatments to answer this question; is the most effective drug is linked to the best quality of life.

Eligibility criteria:
inclusion criteria: * we will recruit patients with primary chronic itp patients with itp lasting for more than 12 months which is proved to be refractory to the standard first line treatment or need to treatment(s) (including, but not limited to, low dose of corticosteroids) to minimize the risk of clinically significant bleeding. * subject or their guardian has signed and dated a written informed consent. * subject experienced no toxicity or known contraindication to any line of treatments. exclusion criteria: * pregnancy. * liver and kidney function impairment. * hepatitis c virus(hcv), human immunodeficiency virus (hiv), hepatitis b virus infection. * patients with systemic lupus erythematosus and/or antiphospholipid syndrome * lymphoproliferative disorders. * an active malignancy * an arterial or venous thrombosis * grade iii-iv cardiovascular disease . * recent history of alcohol/drug abuse. * subjects recently treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or nsaids) or anti-coagulants for \> 3 consecutive days within 2 weeks of the study start and until the end of the study.
a rehabilitation program for adolescents with chronic fatigue syndrome

Conditions: Chronic Fatigue Syndrome

Summary: the aim of the programme is to develop a treatment model for adolescents with chronic fatigue syndrome. the program consists of 4 elements lasting for 12 months, psychoeducation reflecting the current knowledge about the disease, heart rate variability coherence biofeedback, pacing and activity planning and some principles of cognitive behaviour therapy. the study is designed as a single-case study including 10- 15 participants.


Eligibility criteria:
inclusion criteria: * participants who meet the diagnostic criteria of chronic fatigue syndrome * clinically evaluated, exclude any disease that can explain the chronic fatigue; * diagnosed and evaluated within the health region, central norway * with written consent form signed by themselves and their parents. exclusion criteria: * serious comorbidity such as anorexia, psychosis * serious depression

Keywords: rehabilitation adolescent heart rate variability biofeedback psychoeducation
endoscopic size assessment of advanced adenomatous polyps

Conditions: Adenoma Detection Rate Improvement in Screening Colonoscopy

Summary: the investigators are retrospectively comparing detection rates of adenomatous polyps, advanced adenomas, and size assessment of the polyps among rush university medical center endoscopists. the investigators plan to review whether the size assessment of adenomatous polyps affected the surveillance protocols and if the location of polyps detected affected the detection rates.

the study plans to compare detection rates of adenomatous as well as the sessile serrated polyps, advanced adenomas and size assessment of the polyps among the endoscopists at the study site. in addition, the study team aims to evaluate rates of advanced neoplasia on surveillance colonoscopy based on certain features on initial colonoscopy and patient characteristics, including specific high-risk histologic features and concurrent medication usage such as aspirin. in addition, patients with at least one adenoma on surveillance colonoscopy will be identified and regarded as cases. cases will be compared against normal surveillance colonoscopy. the controls will be selected on a 1:1 ratio. aspirin use will be compared between groups.

Eligibility criteria:
inclusion criteria: * presence of adenomatous polyps detected at endoscopy and diagnosed pathologically by tissue biopsy * have a colonoscopy at rumc for screening purposes exclusion criteria: * failure to meet inclusion criteria * previous diagnosis of ibd or colorectal cancer

Keywords: colonoscopy adenoma adr screening colon cancer
gerd after sleeve gastrectomy

Conditions: Morbid Obesity; GERD

Summary: the main adverse effect is gastroesophageal reflux disease (gerd), with concern on the development of barrett's esophagus and esophageal adenocarcinoma in the long term. however, the relationship between sg and gerd is complex. the aim of this study is to systematically evaluate all published data existing in the literature to evaluate the effect of sleeve gastrectomy on gerd, esophagitis, be in order to clarify the long-term clinical sequelae of this procedure. this systematic review was conducted in accordance with the guidelines for preferred reporting items for systematic review and meta-analyzes (prisma). published studies that contained outcome data for primary sleeve gastrectomy associated with the primary and secondary outcomes listed below were included.


Eligibility criteria:
inclusion criteria: * patients underwent to sleeve gastrectomy with reflux symptoms exclusion criteria: * patients underwent to other bariatric procedures